Cover Image

Addressing existing gaps in the management of young adults with atopic dermatitis

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Magdalena Trzeciak, Weronika Zysk
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Journal of the European Academy of Dermatology and Venereology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

French guidelines for the management of atopic dermatitis
by: Nina Sigg, et al.
Published: (2025)

Bridging the gap: Treatment of atopic dermatitis with dupilumab during pregnancy
by: Christian Vestergaard, et al.
Published: (2025)

Drug utilization among young adults with atopic dermatitis: Influence of sex, socio‐economic status and disease severity
by: P. L. Carmanius, et al.
Published: (2024)

Drug survival of abrocitinib compared to dupilumab in adult patients with atopic dermatitis
by: Qingjie Hu, et al.
Published: (2024)

Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis
by: Lian F. van der Gang, et al.
Published: (2026)

The long road to atopic disease modification in infants with atopic dermatitis
by: Thomas Hultsch
Published: (2024)

Phototherapy for atopic dermatitis: Is the light still shining?
by: Adrian Tanew
Published: (2024)

Fracture risk among adults with atopic dermatitis: A population‐based cohort study in the United Kingdom
by: Zelma C. Chiesa Fuxench, et al.
Published: (2025)

Psychological impact on flare patterns and severity of atopic dermatitis
by: Mia‐Louise Nielsen, et al.
Published: (2024)

Langerhans cells: Central players in the pathophysiology of atopic dermatitis
by: Yi Pan, et al.
Published: (2024)

An alternative interpretation of the diagnosis of atopic dermatitis in the Boy with an Orange
by: Nicolas Kluger
Published: (2026)

Infectious risk with JAKi : What about atopic dermatitis?
by: Lea Hoisnard, et al.
Published: (2025)

T helper and IL ‐20 cytokine signatures distinguish atopic dermatitis from contact dermatitis subtypes
by: Axel De Greef, et al.
Published: (2025)

Leveraging artificial intelligence to pursue treatment personalization in atopic dermatitis
by: Bruno Duarte
Published: (2024)

Dissecting the roles of oxidative stress gene expression in atopic dermatitis
by: Zhi‐Qing Zhan, et al.
Published: (2024)

Tattoos in patients with atopic dermatitis: What the dermatologist should know?
by: Nicolas Kluger
Published: (2025)

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis
by: Tiago Torres, et al.
Published: (2026)

Impact of prior biologic exposure on drug survival in atopic dermatitis
by: Xu Li, et al.
Published: (2025)

Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab
by: Andrew Blauvelt, et al.
Published: (2025)

Correspondence to ‘Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis’
by: Shiuan‐Chih Chen, et al.
Published: (2025)

Interpreting the risk of venous thromboembolism with JAK inhibitors in atopic dermatitis
by: Sheng Li, et al.
Published: (2025)

Stratum corneum and microbial biomarkers precede and characterize childhood atopic dermatitis
by: Melina Fonfara, et al.
Published: (2024)

Fears for tears? Targeted therapies for atopic dermatitis and ocular surface health
by: Carolyn Jack, et al.
Published: (2024)

Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity
by: Joséphine Dupuis, et al.
Published: (2024)

New bricks in the wall regarding the link between obesity and atopic dermatitis
by: Teofila Seremet
Published: (2024)

Dupilumab facial dermatitis in atopic dermatitis patients ameliorated by topical crisaborole: An open‐label case series study
by: Han‐Wen Lin, et al.
Published: (2024)

Real‐world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis
by: Teppei Hagino, et al.
Published: (2025)

Reply to comments by Tadulewicz and Muklewicz on socio‐economic outcomes of atopic dermatitis
by: Sigrun Alba Johannesdottir Schmidt, et al.
Published: (2025)

Psychotherapeutic interventions improve disease severity and quality of life in atopic dermatitis
by: Genevieve Arany‐Lao‐Kan, et al.
Published: (2025)

Understanding socioeconomic outcomes in Danish children with moderate‐to‐severe atopic dermatitis
by: Ilona Tadulewicz, et al.
Published: (2025)

Sexual orientation and gender identity in clinical trials of atopic dermatitis and psoriasis
by: Michael J. Martinez, et al.
Published: (2025)

Critical methodological enhancements for JAK inhibitor safety studies in atopic dermatitis
by: Zheying Huang, et al.
Published: (2025)

Methotrexate for atopic dermatitis: The right dosing and best‐performance administration route
by: A. Nosbaum, et al.
Published: (2025)

Detecting T‐cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab
by: Hyungdon Kook, et al.
Published: (2024)

The wide spectrum of disease burden in atopic dermatitis—Implications for more holistic approaches?
by: Alexander Salava
Published: (2024)

Single‐centre experience with tralokinumab in dupilumab‐experienced and naïve patients with atopic dermatitis
by: Claire Fossati, et al.
Published: (2024)

International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study
by: Anouk G. M. Caron, et al.
Published: (2024)

Primary localized cutaneous amyloidosis associated with atopic dermatitis treated successfully with nemolizumab
by: Takeshi Fukumoto, et al.
Published: (2024)

Disproportionate quality of life decline and unaddressed limitations in amlitelimab atopic dermatitis trial
by: Shiuan‐Chih Chen, et al.
Published: (2025)

Thromboembolic risk with JAK inhibitors in atopic dermatitis: Context, caution and clinical relevance
by: Joseph V. Caravaglio
Published: (2025)